



ACNE, ROSACEA, AND RELATED DISORDERS (INCLUDING HIDRADENITIS SUPPURATIVA)

TOLERANCE AND EFFICACY OF A DERMOCOSMETIC PRODUCT CONTAINING MYRTACINE® AND AZELAIC ACID IN THE MANAGEMENT OF ACNE IN AFRICAN WOMEN.

V Mengeaud⁽¹⁾ - M Diallo⁽²⁾ - M Kaloga⁽³⁾ - Be Degboe Kay⁽⁴⁾ - S Chehadi⁽⁵⁾ - Pe Happi⁽⁶⁾ - L Liegard⁽¹⁾

Pierre Fabre Dermocosmetique, Medical Affairs Department, Lavour, France⁽¹⁾ - Cheikh Anta Diop University, Department Of Dermatology, Dakar, Senegal⁽²⁾ - Treichville Teaching Hospital, Department Of Dermatology, Abidjan, Ivory Coast⁽³⁾ - National Teaching Hospital, Department Of Dermatology, Cotonou, Benin⁽⁴⁾ - Private Practice, Dermatologist, Dakar, Senegal⁽⁵⁾ - Private Practice, Dermatologist, Douala, Cameroon⁽⁶⁾

Introduction/Objectives: Acne is very common in African women and often lead to post-inflammatory hyperpigmentation (PIH). The objectives of the study were to evaluate the anti-acne and anti-PIH efficacy and tolerance of a dermocosmetic product containing myrtacine® and azelaic acid.

Materials/Methods: This was an observational study conducted by 5 dermatologists of 4 African countries, including 75 consenting women (skin phototype III/VI) with mild to moderate acne and PIH. The dermocosmetic product, alone or in combination with anti-acneic treatments, was applied daily for 12 weeks. The evaluation was based on acne severity (GEA Scale), lesion counting (including PIH) and IGA. The evaluation of cutaneous tolerance was also done.

Results: In the subgroup using the product alone, we observed after 3 months of use:

- A highly significant improvement of the GEA score ($p < 0.001$)
- A highly significant decrease of the number of comedones and papules ($p < 0.001$)
- A highly significant improvement of PIH and IGA; ($p < 0.001$)

In the subgroup using the dermocosmetic product in combination with anti-acneic treatment, we observed a good and very good cutaneous tolerance in 93.4% of women after 3 months of use.

Conclusion: The results of this observational study showed the interest of a dermocosmetic product containing myrtacine® and azelaic acid in the management of acne lesions and PIH in African women, alone or in combination with anti-acneic treatment.

